ArticleApplied health economics and health policy2023

Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.

Jaesh Naik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.